In addition to the ongoing humanitarian emergencies in the country, the COVID-19 pandemic poses a potential monumental social and economic threat to Nigeria, with a devastating knock on effect for the most vulnerable population in the BAY states who have endured a decade of conflict. The UN system i...n Nigeria launched a One UN Response Plan to COVID-19 to support the rapid implementation of the Government’s National COVID-19 Multi-Sectoral Pandemic Response Plan and will continue to support strong coordination and coherence with all stakeholders responding to the pandemic.
more
The National Guideline for Neonatal Care and Establishment of Neonatal Care Unit aims to provide health workers with all basics and necessary knowledge and skills to provide appropriate care at the most vulnerable period in a newborn’s life. This guideline will be available to all health facilitie...s as a reference book for health workers. The book contains up-to-date evidence-based information and management of newborns with a range of needs in the initial newborn period
more
Aupres des jeunes, adolescents et la population dans les ZS de Kanzahla et de Tshikapa du 12 au 17/9/2018
THELANCETID-D-16-00800 S1473-3099(16)30318-8
The Lancet Volume 5, Issue 10100972October 2024 Chagas Disease Serie 3
The information provided here can be used to understand the current situation, increase attention to preterm births in Rwanda and to inform dialogue and action among stakeholders. Data can be used to identify the most important risk factors to target and gaps in care in order to identify and impleme...nt solutions for improved outcomes.
more
you can find branded materials including immunization backgrounders, posters, social media posts and more to amplify your existing activities and facilitate any communications for the week. Please feel free to tailor and adapt materials to meet specific country
New criteria for classifying and diagnosing hyperglycaemia first detected during pregnancy have been accepted by a group of experts convened by WHO. These new criteria are an update of recommendations published by WHO in 1999
The aim of this article is to identify the elements behind the country’s successful COVID-19 rollout as well as lessons and chal lenges derived from this process. The analysis is relevant to many countries today—as they keep searching for strategies to cope with the second year of the COVID-19 p...andemic and the challenge of implementing a large-scale vaccine rollout—and in the coming years—as new variants develop and unceertainty about the vaccination strategy increases.
more
Le livret aborde les différents besoins d'assainissement et d'hygiène des femmes et des hommes. Il donne des informations permettant de réaliser des progrès significatifs en matière d'assainissement par une meilleure utilisation des compétences et des ressources autochtones locales. Il est con...çu pour être une partie importante de l'Initiative communautaire pour l'eau, encourageant les communautés à prendre en charge leur développement sanitaire pour une vie meilleure.
more
DHS Working Papers No. 120
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more